Issues in the economic evaluation of treatment for dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

Alzheimer Disease and Associated Disorders

Volumn 11, Issue SUPPL. 3, 1997, Pages 39-45

  Winblad, Bengt ^a   Hill, Suzanne ^b   Beermann, Björn ^c   Post, Stephen G ^d   Wimo, Anders ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; CULTURAL FACTOR; DEMENTIA; DRUG COST; ECONOMICS; EUROPE; FORECASTING; HEALTH CARE COST; HUMAN; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; TREATMENT OUTCOME; UNITED STATES;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; CROSS-CULTURAL COMPARISON; DEMENTIA; DRUG COSTS; EUROPE; FORECASTING; HEALTH CARE COSTS; HUMANS; INTERNATIONAL COOPERATION; NOOTROPIC AGENTS; PRACTICE GUIDELINES; TREATMENT OUTCOME; UNITED STATES;

EID: 0030634555     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Baker AM. Practical aspects of designing and conducting pharmacoeconomic studies. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers, 1996:1113-21.
2. Coughlin TA, Liu K. Health care costs of older persons with cognitive impairments. Gerontologist 1989;29:173-82.
3. Drummond M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ 1992;1:85-92.
4. Drummond M, Stoddart GL, Torrance GEW. Methods for the economic valuation of health care programmes. Oxford, U.K.: Oxford University Press, 1987.
5. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1-4.
6. Feeny DH, Torrance GW, Furlong WJ. Health utilities index. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers, 1996:239-52.
7. Fratiglioni L, Viitanen M, Bäckman L, Sandman PO, Winblad B. Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 1992;11(Suppl):29-36.
8. Freund DA, Sittus RS. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics 1992;1:20-32.
9. Fries BE, Mehr DR, Schenider D, Foley WJ, Burke R. Mental dysfunction and resource use in nursing homes. Med Care 1993;31:898-920.
10. Gottfries CG, Bråne G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982;11:311-30.
11. Gray AM. The economic impact of Alzheimer's disease. Rev Contemp Pharmacother 1995;6:327-34.
12. Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am J Public Health 1987;77:1169-75.
13. Hu T, Lien-Fu H, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986;26:158-63.
14. Kaplan RM, Andersson JP. The general health policy model: an integrated approach. In: Spiker B, ed. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996.
15. Knopman D. Tacrine for Alzheimer's disease: costs and benefits. Pharmacoeconomics 1995;4:275-9.
16. Knopman D. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.
17. Manton KG, Corder LS, Clark R. Estimates and projections of dementia-related service expenditures. In: Suzman R, Singer B, Manton K, eds. Forecasting the health of the oldest old. New York: Springer-Verlag, 1993.
18. Max W, Webber P, Fox P. Alzheimer's disease: the unpaid burden of caring. J Aging Health 1995;7:179-99.
19. National Board of Health and Welfare, Sweden. Follow-ups and evaluations 1994: 1. The new fees for the elderly and the handicapped. Stockholm: The National Board of Health and Welfare (NBHW), 1994. [In Swedish.]
20. OECD. OECD health data/ECO-Sante-OCDE. Paris: Organization for Economic Co-operation and Development. 1995. [Data file.]
21. Østbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994;151:1457-64.
22. Overman W, Stoudmire A. Guidelines for legal and financial counseling of Alzheimer's disease patients and their families. Am J Psychiatry 1988;145:1495-500.
23. Powell Lawton M. Quality of life in Alzheimer disease. Alzheimer Dis Assoc Disord 1994;8(Suppl 1):138-50.
24. Reisberg B, Borenstein J, Franssen L, et al. BEHAVE-AD: a clinical rating scale for the assessment of pharmacologically remediable behavioural symptomatology in Alzheimer's disease. In: Altman K, ed. Alzheimer's disease: problems, prospects and perspectives. New York: Plenum, 1987:1-16.
25. Rockwood K. Use of global assessment measures in dementia drug trials. J Clin Epidemiol 1994;47:101-3.
26. Sacristan JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilization of a checklist. Ann Pharmacother 1993;27:1126-33.
27. Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990;263:2335-40.
28. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
29. Severson MA, Smith GE, Tangalos EG, et al. Patterns and predictors of institutionalization in community-based dementia patients. J Am Geriatr Soc 1994;42:181-5.
30. Sonnenberg FA, Beck JR. Markov models in decision making: a practical guide. Med Decis Making 1993;13:322-38.
31. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-600.
32. Thorslund M. The de-institutionalization of care of the elderly: some notes about implementation and outcome of a Swedish case-study. Health Policy 1988;10:44-56.
33. Weinstein MC, Feinherg H. Clinical decision analysis. Philadelphia: W. B. Saunders, 1980.
34. Wimo A, Karlsson G, Sandman PO, Winblad B. Care of the demented - a time bomb of costs? Nord Med 1995;110:123-6. [In Swedish with an English summary.]
35. Wimo A, Mattsson B, Gustafsson L. Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders. Scand J Prim Health Care 1992;10:185-91.